GHK-Cu (0.5%) : A copper peptide known for its skin-regenerating properties, helping improve elasticity, firmness, and overall skin tone
Read More Rethinking Hyperhidrosis Management: Evidence-Based Compounded Solutions Understanding Primary Focal Hyperhidrosis Primary focal hyperhidrosis is a chronic condition affecting approximately 5% of the population, characterized by excessive sweating of the axillae, palms, soles, or faceoften beginning in adolescence
Shimada K, Filipuzzi I, Stahl M, Helliwell SB, Studer C, Hoepfner D, et al
Evaluation method Results were assessed using three methods: (1) SALT (Severity of Alopecia Tool) scoring, (2) blinded dermatologist evaluation of before/after photographs, and (3) AI-assisted assessment using ChatGPT
FOXO4-DRI vs nearby senolytics Option FOXO4-DRI Type D-retro-inverso peptide Human trial stage None (preclinical only) Option Dasatinib + Quercetin (D+Q) Type Small-molecule drug + flavonoid Human trial stage Early human trials (e.g., Alzheimer's) Option Navitoclax Type BCL-2 family inhibitor Human trial stage Later-stage trials (e.g., myelofibrosis) D+Q and navitoclax are further along in humans but can affect healthy cells (e.g., low platelets)
